PeptideDB

Sublancin

CAS: 207410-26-2 F: C162H254N50O51S5 W: 3878.38

Sublancin is an antimicrobial peptide, which inhibits DNA replication, transcription and translation, without affecting
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Sublancin is an antimicrobial peptide, which inhibits DNA replication, transcription and translation, without affecting membrane integrity. Sublancin suppresses glucose uptake for the competition of phosphotransferase system (PTS). Sublancin inhibits B. subtilis strain 168 ΔSPβ with MIC of 0.312 μM[1][2].
Invitro Sublancin (0-500 μM, 24 h) 抑制耐甲氧西林金黄色葡萄球菌 (MRSA),MIC 为 15 μM,并且在 RAW246.7 巨噬细胞、小鼠腹膜巨噬细胞和人 Caco-2 253 上皮细胞中没有表现出细胞毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Sublancin 相关抗体: Cell Viability Assay[1] Cell Line:
In Vivo Sublancin (0.5-4 mg/kg,腹腔注射,单剂量) 通过诱导 IL-6 和 MCP-1,改善 MRSA 感染小鼠模型中的 MRSA 感染,通过抑制 NF-κB 激活减轻肠道炎症[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS 207410-26-2
Sequence Gly-Leu-Gly-Lys-Ala-Gln-Cys-Ala-Ala-Leu-Trp-Leu-Gln-Cys-Ala-Ser-Gly-Gly-Thr-Ile-Gly-{Cys(D-glucopyranosyl)}-Gly-Gly-Gly-Ala-Val-Ala-Cys-Gln-Asn-Tyr-Arg-Gln-Phe-Cys-Arg (disulfide bridge: Cys7-Cys36, Cys14-Cys29)
Shortening GLGKAQCAALWLQCASGGTIG-{Cys(D-glucopyranosyl)}-GGGAVACQNYRQFCR (disulfide bridge: Cys7-Cys36, Cys14-Cys29)
Formula C162H254N50O51S5
Molar Mass 3878.38
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Wang S, et al., Use of the Antimicrobial Peptide Sublancin with Combined Antibacterial and Immunomodulatory Activities To Protect against Methicillin-Resistant Staphylococcus aureus Infection in Mice. J Agric Food Chem. 2017 Oct 4;65(39):8595-8605. [2]. Wu C, et al., Investigations into the Mechanism of Action of Sublancin. ACS Infect Dis. 2019 Mar 8;5(3):454-459.